Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca–Charles River Laboratories strategic relationship
| Autor: | Ruth MacLean, David M. Hollinshead, Claire Landqvist, Frederic D.C. Martin, Amanda Benjamin |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pharmacology
Engineering Drug Industry Safety studies business.industry Safety pharmacology Drug Evaluation Preclinical Outsourced Services Efficiency Organizational 030226 pharmacology & pharmacy Outsourcing 03 medical and health sciences Engineering management 0302 clinical medicine Workflow Models Organizational 030220 oncology & carcinogenesis Drug Discovery Cooperative behavior Cooperative Behavior Laboratories business ADME |
| Zdroj: | Drug Discovery Today. 22:1754-1759 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2017.08.007 |
| Popis: | In 2012, AstraZeneca entered into a strategic relationship with Charles River Laboratories whereby preclinical safety packages comprising safety pharmacology, toxicology, formulation analysis, in vivo ADME, bioanalysis and pharmacokinetics studies are outsourced. New processes were put in place to ensure seamless workflows with the aim of accelerating the delivery of new medicines to patients. Here, we describe in more detail the AstraZeneca preclinical safety outsourcing model and the way in which a collaborative tool has helped to translate the processes in AstraZeneca and Charles River Laboratories into simpler integrated workflows that are efficient and visible across the two companies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect